Blopress (Takeda Pharmaceutical)
Patent expiry: June 2012

2012 sales: $1.643 billion
2011 sales: $1.808 billion
Change: (9%)

There is not much to be said about the antihypertensive drug Blopress, which has been a solid seller for Takeda, a company that has been defined by Actos. That Type 2 diabetes treatment accounted for more than half of Takeda's U.S. revenues and 18% of its overall sales before going off patent in August.

But Blopress has also lost patent protection, and the Japanese drugmaker is already seeing the effects. Its fiscal year ended March 31, and it recently reported that sales for Blopress were off 22% during those 12 months. With two of its blockbusters under generic siege, the company has laid off 2,800 people in the U.S. and Europe to preserve margins as much as it can while it searches for drugs to take their place.

Takeda has a new lineup of execs, including Dr. Tadataka "Tachi" Yamada, who was tapped to engineer a turnaround in the company's R&D program. It recently won FDA approval for its new diabetes franchise, which revolves around the active ingredient alogliptin. The drugmaker also paid $13 billion in 2011 to pick up Swiss drugmaker Nycomed as part of its strategy to diversify from its reliance on the Japanese and U.S. markets and expand in Europe and, more particularly, in emerging markets.

For more:
Takeda aims to backfill Actos sales with new diabetes franchise
Takeda's Actos era ends with generic launches


Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.